|
|
9601 Medical Center Dr
Rockville, MD 20850 USA
phone:(205) 909-3751
fax:(205) 909-3742
|
|
| Symbol |
Private |
| Founded |
1997 |
| Employees |
8 |
|
|
| www.vaxin.com
|
|
|
|
 |
| Summary Description |
| Vaccine company using non-invasive means to elicit immune responses. |
|
| Management |
| Bill Enright, President & CEO;
Henrik Rasmussen, MD, PhD, CMO (consultant);
Kent Van Kampen, DVM, PhD, COO;
De-chu Tang, PhD, CTO and Scientific founder |
| |
|
|
| |
|
| Keywords |
| Elicit Immune Responses, Nasal Mucosa, Influenza Vaccine, Non-Replicating Vaccine, Anthrax Vaccines, Bacillus Anthracis, Avian Influenza Vaccines. |
|
|
|
| Description |
|
Vaxin is a clinical stage vaccine development company developing novel, needle-free, intransally administered vaccines against influenza and other infectious disease and biodefense agents. We have solid Phase I data, established strategic partners and near term milestone events that provide a strong value proposition. We are working to secure a $20M Series B financing to advance our influenza program through Ph II. |
|
| Products / Services |
Seasonal Influenza Vaccine
Pre-pandemic Influenza Vaccines
Anthrax Vaccines
|
|
| Technology / Differentiation |
| Intranasally administered, recombinant, cell-culture manufactured, self-adjuvanting vaccines. Based on replication incompetent adenovirus manufactured in PER.C6 cell line (licensed from Crucell). |
|
| Market / Customers |
Annually more than 36,000 people in the US die each year as a result of influenza, primarily in the >60 year old age group. There is a significant unmet need for vaccines to adequately protect against influenza infections in this patient population. We believe the combination of a self-adjuvanting, intranasally administered vaccine will provide a significant increase in efficacy in this and other hard to protect patient populations.
|
|
| Status |
Ph I Seasonal Influenza Vaccine Study - successfully completed
Ph I Pre-pandemic (H5N1) Influenza Vaccine Study - successfully completed
$10M raised to date + $20M non-dilutive capital
Currently looking to raise $20M Series B |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members